Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fausto Castagnetti

Showing results (51-60 of 158) with videos related to

Pageof 16
Sort By:
Leukemia|November 25, 2023
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND studyGianantonio Rosti, Tim H Brümmendorf, Björn T Gjertsen, et al.
Oncotarget|April 14, 2017
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapySimona Luatti, Carmen Baldazzi, Giulia Marzocchi, et al.
Leukemia Research|June 2, 2009
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinibMassimo Breccia, Francesca Palandri, Anna Paola Iori, et al.
Cancer|April 21, 2012
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapyMarzia Defina, Micaela Ippoliti, Alessandro Gozzetti, et al.
Journal of Clinical Medicine|August 26, 2023
Italian Physicians' Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA SurveyMassimo Breccia, Alfonso Piciocchi, Elisabetta Abruzzese, et al.
Journal of Cellular Biochemistry|April 13, 2017
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation AdvantageManuela Mancini, Fausto Castagnetti, Simona Soverini, et al.
Leukemia|July 30, 2022
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemiaSimona Soverini, Sara De Santis, Margherita Martelli, et al.
Oncotarget|May 19, 2018
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patientsMaria Rosaria Ricciardi, Valentina Salvestrini, Roberto Licchetta, et al.
Frontiers in Oncology|December 4, 2025
GIMEMA survey on the management of chronic myeloid leukemia patients in the third line and beyond: insights from Italian hematologistsMassimo Breccia, Alfonso Piciocchi, Elisabetta Abruzzese, et al.
Human Genomics|September 19, 2022
Immune dysregulation associated with co-occurring germline CBL and SH2B3 variantsFrancesco Baccelli, Davide Leardini, Edoardo Muratore, et al.
Pageof 16

Showing results (51-60 of 158) with videos related to

Sort By:
Pageof 16
Leukemia|November 25, 2023
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND studyGianantonio Rosti, Tim H Brümmendorf, Björn T Gjertsen, et al.
Oncotarget|April 14, 2017
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapySimona Luatti, Carmen Baldazzi, Giulia Marzocchi, et al.
Leukemia Research|June 2, 2009
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinibMassimo Breccia, Francesca Palandri, Anna Paola Iori, et al.
Cancer|April 21, 2012
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapyMarzia Defina, Micaela Ippoliti, Alessandro Gozzetti, et al.
Journal of Clinical Medicine|August 26, 2023
Italian Physicians' Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA SurveyMassimo Breccia, Alfonso Piciocchi, Elisabetta Abruzzese, et al.
Journal of Cellular Biochemistry|April 13, 2017
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation AdvantageManuela Mancini, Fausto Castagnetti, Simona Soverini, et al.
Leukemia|July 30, 2022
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemiaSimona Soverini, Sara De Santis, Margherita Martelli, et al.
Oncotarget|May 19, 2018
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patientsMaria Rosaria Ricciardi, Valentina Salvestrini, Roberto Licchetta, et al.
Frontiers in Oncology|December 4, 2025
GIMEMA survey on the management of chronic myeloid leukemia patients in the third line and beyond: insights from Italian hematologistsMassimo Breccia, Alfonso Piciocchi, Elisabetta Abruzzese, et al.
Human Genomics|September 19, 2022
Immune dysregulation associated with co-occurring germline CBL and SH2B3 variantsFrancesco Baccelli, Davide Leardini, Edoardo Muratore, et al.
Pageof 16